Steven D. Harr left the role of Director at Sana Biotechnology, Inc. As of November 6, 2026, Sana Biotechnology, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 24, 2026, naming 1 departure (Form 8-K, April 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Sana Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Sana Biotechnology, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-24. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Sana Biotechnology, Inc. files it.
Also on the record for Sana Biotechnology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Robert Nelsen | 15.4% of the class | 5%+ stakes | Source |
| May 21, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 6.3% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Robert Nelsen | 17.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sana Biotechnology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Sana Biotechnology, Inc. and the records around it.
Sana Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Lyell Immunopharma, Inc. (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Sana Biotechnology, Inc.
Get an email when Sana Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sana Biotechnology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sana Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sana Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-24 | Out | Director | 8-K, 2026-04-24 |
Who leads Sana Biotechnology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Steven D. Harr, departure reported (filed 2026-04-24). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Sana Biotechnology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Sana Biotechnology, Inc., with the record behind each one.
Find candidates like Director at Sana Biotechnology, Inc.Every change, in the filing's words
Departing: Steven D. Harr, Director
Accordingly, on April 22, 2026, contingent upon and effective as of immediately prior to his re-appointment to the Board as a Class III director, Steven D. Harr, M.D., tendered his resignation from his position as a Class I director to the Board, and on the same date, the Board accepted such resignation and immediately re-appointed him as a Class III director.
- In order to achieve a more equal balance of director membership among the three classes of the Board of Directors ("Board") of Sana Biotechnology, Inc. (the "Company") in accordance with the Company's Amended and Restated Certificate of Incorporation ("Certificate of Incorporation"), the Board determined that one of its Class I directors (with a term expiring at the Company's 2028 annual meeting of stockholders) should be reclassified to a Class III director (with a term expiring at the Company's 2027 annual meeting of stockholders).
- The foregoing actions were effected solely to rebalance the Board classes in order to comply with the Certificate of Incorporation, and Dr. Harr's service on the Board is deemed to have continued uninterrupted.
Tools for this story
Each opens in a new tab, filled in for Sana Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.